We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

4 hedge funds and large institutions have $4.15M invested in Intra-Cellular Therapies Inc. in 2025 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 389 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less funds holding

Funds holding: 395 → 4 (-391)

100% less capital invested

Capital invested by funds: $13.6B → $4.15M (-$13.6B)

100% less funds holding in top 10

Funds holding in top 10: 52 → 0 (-52)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 389

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
4
Holders Change
-391
Holders Change %
-98.99%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
-52
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
2
Closed
389
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$1.26B
2
BlackRock
BlackRock
New York
-$1.15B
3
PCM
Pentwater Capital Management
Florida
-$685M
4
HI
HBK Investments
Texas
-$578M
5
Norges Bank
Norges Bank
Norway
-$472M
Name Holding Trade Value Shares
Change 		Change in
Stake
X
201
Xponance
Pennsylvania
– -$1.86M -14,093 Closed
QT
202
Quantbot Technologies
New York
– -$1.72M -13,020 Closed
Wealth Enhancement Advisory Services
203
Wealth Enhancement Advisory Services
Minnesota
– -$1.66M -12,576 Closed
Pathstone Holdings
204
Pathstone Holdings
New Jersey
– -$1.63M -12,380 Closed
AWA
205
Arete Wealth Advisors
Illinois
– -$1.6M -12,117 Closed
Victory Capital Management
206
Victory Capital Management
Texas
– -$1.57M -11,938 Closed
SC
207
Sagefield Capital
Texas
– -$1.56M -11,800 Closed
KC
208
Kintayl Capital
New York
– -$1.52M -11,516 Closed
Bank of Nova Scotia
209
Bank of Nova Scotia
Ontario, Canada
– -$1.5M -11,400 Closed
Universal-Beteiligungs- und Servicegesellschaft
210
Universal-Beteiligungs- und Servicegesellschaft
Germany
– -$1.48M -11,251 Closed
BCM
211
BCK Capital Management
Connecticut
– -$1.45M -11,000 Closed
American Century Companies
212
American Century Companies
Missouri
– -$1.42M -10,773 Closed
FGP
213
Freestone Grove Partners
California
– -$1.37M -10,404 Closed
Public Employees Retirement Association of Colorado
214
Public Employees Retirement Association of Colorado
Colorado
– -$1.33M -10,057 Closed
BCM
215
Bluefin Capital Management
New York
– -$1.32M -10,000 Closed
COPPSERS
216
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
– -$1.32M -10,000 Closed
MTCM
217
Mint Tower Capital Management
Netherlands
– -$1.25M -9,500 Closed
PD
218
Point72 (DIFC)
United Arab Emirates
– -$1.24M -9,382 Closed
JSSH
219
J. Safra Sarasin Holding
– -$1.16M -8,799 Closed
CC
220
Centiva Capital
New York
– -$1.15M -8,705 Closed
Russell Investments Group
221
Russell Investments Group
United Kingdom
– -$1.1M -8,336 Closed
VPIM
222
Vanguard Personalized Indexing Management
California
– -$1.09M -8,280 Closed
Walleye Trading
223
Walleye Trading
New York
– -$1.06M -8,000 Closed
AB
224
Amalgamated Bank
New York
– -$983K -7,452 Closed
GCP
225
GSA Capital Partners
United Kingdom
– -$973K -7,376 Closed
7 8
9
10 11

ITCI Hedge Fund Activity: Q2 2025 in Review

4 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q2 2025, worth a combined $4.15M — down 100% from $13.6B a quarter earlier.

Sellers outnumbered buyers: 389 funds closed out of ITCI and 0 opened new positions — a net loss of 389 holders — while 2 trimmed existing stakes and 0 added.

The largest seller was Vanguard Group, exiting entirely with an estimated $1.26B sold.

  • 4 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q2 2025, down from 395 in Q1 2025.
  • Funds reported $4.15M of Intra-Cellular Therapies Inc. stock for Q2 2025, down 100% quarter-over-quarter.
  • 0 funds opened new Intra-Cellular Therapies Inc. positions in Q2 2025 and 389 closed out, a net change of -389 holders.
  • The largest Intra-Cellular Therapies Inc. seller in Q2 2025 was Vanguard Group, an estimated $1.26B sold.

Based on aggregated 13F filings for Q2 2025.